Q1 2025 IOL Chemicals and Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- The company reported a slight increase in exports for Q1 FY25, reaching INR150 crore compared to INR149 crore in the same period last year.
- India's economy has exceeded growth expectations, averaging 8.3% annual growth, which positively impacts the pharmaceutical sector.
- The company is focusing on expanding its non-ibuprofen API segment, targeting 50% of API revenue from non-ibuprofen products within the next three to four years.
- IOL Chemicals And Pharmaceuticals Ltd (BOM:524164) has received several CEP approvals, which are expected to boost export contributions in the coming quarters.
- The company is maintaining a strong cash position with INR190 crore in the bank, which is earmarked for business expansion and potential opportunities.
- Total income for Q1 FY25 declined to INR510 crore from INR570 crore in the same quarter last year.
- EBITDA for the quarter decreased to INR58 crore from INR80 crore in the corresponding quarter of FY24, with EBITDA margins dropping by 260 basis points.
- Net profit for Q1 FY25 fell to INR30 crore from INR46 crore in the same period last year.
- The company is facing challenges with the US FDA inspection delays, which is affecting approvals for 15 drugs.
- There has been a substantial decline in other expenses, primarily due to high coal prices and freight costs, which may not be sustainable in the long term.
Ladies and gentlemen, Good day and welcome to Q1 FY25 earnings conference call of IOL Chemicals and Pharmaceuticals Limited. From the management, we have Mr. Pardeep Khanna, Chief Financial Officer; Mr. Abhay Raj Singh, Senior Vice President and Company Secretary; and Mr. Rakesh Mahajan, Advisor Finance and Strategic. We also have the Investor Relations team from Adfactors. (Operator Instructions)
Please note that this conference is being recorded I now hand the conference over to Mr. Darshan Mankad from Adfactors PR for opening remarks. Thank you, and over to you, sir.
Thank you, Manav. Good afternoon, everyone. We welcome you to the first quarter FY25 earnings call of IOL Chemicals and Pharmaceuticals Limited. Before we begin the earnings call, I would like to mention that some of the statements made during today's call might be forward-looking in nature, and hence, it may involve risks and uncertainties, including those related to the future financial and operating performance. Please bear with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
